Patents Assigned to Eleusis therapeutics us, inc.
  • Pharmaceutically acceptable salts of psilocin and uses thereof
    Patent number: 11680043
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: June 20, 2023
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz
  • Pharmaceutically acceptable salts of psilocin and uses thereof
    Patent number: 11312684
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: April 26, 2022
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz
  • Method of treatment for ketamine infusion
    Patent number: 11154537
    Abstract: Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 26, 2021
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: John Bryan Clifton, J Cannon Clifton, Mark Alan Moran, Scott Patrick Worrich
  • Method of Treatment for Ketamine Infusion
    Publication number: 20210322384
    Abstract: Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications.
    Type: Application
    Filed: July 1, 2021
    Publication date: October 21, 2021
    Applicant: Eleusis therapeutics us, inc.
    Inventors: John Bryan Clifton, J Cannon Clifton, Mark Alan Moran, Scott Patrick Worrich